Autophagy Inducers In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Autophagy inducers are compounds that enhance cellular autophagy - the process by which cells degrade and recycle misfolded proteins, damaged organelles, and protein aggregates. This therapeutic strategy addresses the accumulation of toxic protein aggregates that characterize neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
Autophagy (specifically macroautophagy) involves the formation of double-membrane autophagosomes that engulf cellular debris and fuse with lysosomes for degradation. Key mechanisms include:
- mTORC1 inhibition: Direct or indirect inhibition of mTOR complex 1 to activate ULK1 kinase complex
- AMPK activation: Energy sensor activation promotes autophagy through ULK1 phosphorylation
- TFEB activation: Transcription factor EB promotes lysosomal biogenesis
- Beclin-1 complex modulation: Enhance VPS34 lipid kinase activity
- Autophagy receptor targeting: p62/SQSTM1 phosphorylation enhances aggregate clearance
- Clear Aβ plaques through enhanced macroautophagy
- Remove damaged mitochondria (mitophagy) to reduce ROS
- Tau clearance via autophagy-lysosomal pathway
- Rapamycin and derivatives in preclinical models
- Enhance α-synuclein clearance
- Mitophagy enhancement to protect dopaminergic neurons
- LRRK2 inhibitor combinations
- PINK1/Parkin pathway activation
- Clear mutant huntingtin (mHTT) aggregates
- Improve mitochondrial function
- Enhance neuronal survival in striatal neurons
- Trehalose shows promise in mouse models
- Remove TDP-43 aggregates
- Enhance SOD1 clearance
- Protect motor neurons
- Combination with riluzole
¶ Key Drug Candidates
| Drug |
Mechanism |
Disease |
Stage |
| Rapamycin (Sirolimus) |
mTORC1 inhibitor |
AD/PD/HD |
Phase II |
| Everolimus |
mTORC1 inhibitor |
AD |
Phase II |
| Trehalose |
mTOR-independent |
HD/PD |
Preclinical |
| Metformin |
AMPK activator |
AD/PD |
Phase II |
| Lithium |
mTOR-independent |
HD/ALS |
Phase II |
| Resveratrol |
AMPK/SIRT1 activator |
AD/PD |
Phase II |
| Carbamazepine |
mTOR-independent |
PD |
Phase I |
| Nicotinamide |
SIRT1 activator |
HD |
Phase I |
| Genistein |
TFEB activator |
AD/PD |
Preclinical |
| Lithium |
GSK-3β + autophagy |
HD |
Phase II |
Autophagy induction offers disease-modifying potential by addressing root causes:
- Aggregate clearance: Direct removal of pathological protein deposits
- Neuroprotection: Mitochondrial quality control
- Anti-inflammatory: Reduce NLRP3 inflammasome activation
- Timing considerations: Early intervention may prevent aggregate formation
- Combination approaches: Synergy with aggregation inhibitors
- Development of brain-penetrant mTOR inhibitors
- mTOR-independent autophagy enhancers (trehalose, carbamazepine)
- TFEB nuclear translocation enhancers
- Autophagy receptor modulators
- Biomarkers for autophagy activation (LC3, p62 turnover)
- Gene therapy approaches (TFEB overexpression)
The study of Autophagy Inducers In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Sarkar S, et al. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteins. Journal of Cell Biology. 2007.
- Rubinsztein DC, et al. Autophagy and misfolded protein clearance in neurodegenerative diseases. Nature Reviews Drug Discovery. 2012.
- Nixon RA. The role of autophagy in neurodegenerative disease. Nature Medicine. 2013.
- Harris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. Nature Reviews Neurology. 2012.
- Fleming A, et al. The different autophagy pathways in neurodegeneration. Journal of Molecular Biology. 2020.
- Menzies FM, et al. Autophagy induction as a therapeutic strategy for neurodegenerative diseases. Molecular Cell. 2017.
- Song JX, et al. Trehalose, an autophagy inducer, ameliorates alpha-synuclein pathology. Autophagy. 2019.
- Kruse R, et al. Metformin activates AMPK to promote autophagy. Nature Reviews Neurology. 2021.